CD8A and neoplasm: Consistent with a vital role in assisting tumors of CD45RA−CCR7− Tregs in vivo, mice treated with no pre-cocultured CD8+ T cells/CD45RA−CCR7− Tregs, or with CD8+ T cells plus IL-10 blocking antibody-treated CD45RA−CCR7− Tregs showed reduced tumor volumes and disease progression at each measurement time point from day 9 (Figure 5a).